Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1991 Oct;67(792):947–952. doi: 10.1136/pgmj.67.792.947

Specific lipid lowering therapy in the management of diabetes.

P N Durrington 1
PMCID: PMC2399159  PMID: 1758809

Full text

PDF
947

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhatnagar D., Durrington P. N. Borderline hypercholesterolaemia: when to introduce drugs. Postgrad Med J. 1989 Aug;65(766):543–552. doi: 10.1136/pgmj.65.766.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borch-Johnsen K., Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987 Jun 27;294(6588):1651–1654. doi: 10.1136/bmj.294.6588.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Borkman M., Chisholm D. J., Furler S. M., Storlien L. H., Kraegen E. W., Simons L. A., Chesterman C. N. Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. Diabetes. 1989 Oct;38(10):1314–1319. doi: 10.2337/diab.38.10.1314. [DOI] [PubMed] [Google Scholar]
  4. Carlson L. A., Olsson G., Ballantyne D. On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemias in type IV and type V hyperlipoproteinaemias. Atherosclerosis. 1977 Apr;26(4):603–609. doi: 10.1016/0021-9150(77)90127-7. [DOI] [PubMed] [Google Scholar]
  5. Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223(5):405–418. doi: 10.1111/j.0954-6820.1988.tb15891.x. [DOI] [PubMed] [Google Scholar]
  6. Durrington P. N., Miller J. P. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia. Atherosclerosis. 1985 May;55(2):187–194. doi: 10.1016/0021-9150(85)90097-8. [DOI] [PubMed] [Google Scholar]
  7. Durrington P. N. Secondary hyperlipidaemia. Br Med Bull. 1990 Oct;46(4):1005–1024. doi: 10.1093/oxfordjournals.bmb.a072438. [DOI] [PubMed] [Google Scholar]
  8. Durrington P. N. Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta. 1980 May 21;104(1):11–23. doi: 10.1016/0009-8981(80)90130-8. [DOI] [PubMed] [Google Scholar]
  9. Fontbonne A., Eschwège E., Cambien F., Richard J. L., Ducimetière P., Thibult N., Warnet J. M., Claude J. R., Rosselin G. E. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989 May;32(5):300–304. doi: 10.1007/BF00265546. [DOI] [PubMed] [Google Scholar]
  10. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  11. Garg A., Bonanome A., Grundy S. M., Zhang Z. J., Unger R. H. Comparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1988 Sep 29;319(13):829–834. doi: 10.1056/NEJM198809293191304. [DOI] [PubMed] [Google Scholar]
  12. Garg A., Grundy S. M. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988 Jan 14;318(2):81–86. doi: 10.1056/NEJM198801143180204. [DOI] [PubMed] [Google Scholar]
  13. Glauber H., Wallace P., Griver K., Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1988 May;108(5):663–668. doi: 10.7326/0003-4819-108-5-663. [DOI] [PubMed] [Google Scholar]
  14. Goldberg R., La Belle P., Zupkis R., Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol. 1990 Sep 18;66(8):16B–21B. doi: 10.1016/0002-9149(90)90436-5. [DOI] [PubMed] [Google Scholar]
  15. Golper T. A., Illingworth D. R., Morris C. D., Bennett W. M. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis. 1989 Apr;13(4):312–320. doi: 10.1016/s0272-6386(89)80038-1. [DOI] [PubMed] [Google Scholar]
  16. Gordon D. J., Rifkind B. M. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989 Nov 9;321(19):1311–1316. doi: 10.1056/NEJM198911093211907. [DOI] [PubMed] [Google Scholar]
  17. Kannel W. B., McGee D. L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979 Jan;59(1):8–13. doi: 10.1161/01.cir.59.1.8. [DOI] [PubMed] [Google Scholar]
  18. Lalor B. C., Bhatnagar D., Winocour P. H., Ishola M., Arrol S., Brading M., Durrington P. N. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet Med. 1990 Mar-Apr;7(3):242–245. doi: 10.1111/j.1464-5491.1990.tb01378.x. [DOI] [PubMed] [Google Scholar]
  19. Manninen V., Elo M. O., Frick M. H., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988 Aug 5;260(5):641–651. [PubMed] [Google Scholar]
  20. Pietri A. O., Dunn F. L., Grundy S. M., Raskin P. The effect of continuous subcutaneous insulin infusion on very-low-density lipoprotein triglyceride metabolism in type I diabetes mellitus. Diabetes. 1983 Jan;32(1):75–81. doi: 10.2337/diab.32.1.75. [DOI] [PubMed] [Google Scholar]
  21. Rabelink A. J., Hené R. J., Erkelens D. W., Joles J. A., Koomans H. A. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet. 1988 Dec 10;2(8624):1335–1338. doi: 10.1016/s0140-6736(88)90870-7. [DOI] [PubMed] [Google Scholar]
  22. Reckless J. P., Betteridge D. J., Wu P., Payne B., Galton D. J. High-density and low-density lipoproteins and prevalence of vascular disease in diabetes mellitus. Br Med J. 1978 Apr 8;1(6117):883–886. doi: 10.1136/bmj.1.6117.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Seviour P. W., Teal T. K., Richmond W., Elkeles R. S. Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention. Diabet Med. 1988 Mar;5(2):166–171. doi: 10.1111/j.1464-5491.1988.tb00965.x. [DOI] [PubMed] [Google Scholar]
  24. Shepherd J., Betteridge D. J., Durrington P., Laker M., Lewis B., Mann J., Miller J. P., Reckless J. P., Thompson G. R. Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) 1987 Nov 14;295(6608):1245–1246. doi: 10.1136/bmj.295.6608.1245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation. 1989 Oct;80(4):1070–1078. doi: 10.1161/01.cir.80.4.1070. [DOI] [PubMed] [Google Scholar]
  26. Thompson G. R. Evidence that lowering serum lipids favourably influences coronary heart disease. Q J Med. 1987 Feb;62(238):87–95. [PubMed] [Google Scholar]
  27. Trowell H. Diabetes mellitus death-rates in England and Wales 1920-70 and food supplies. Lancet. 1974 Oct 26;2(7887):998–1002. doi: 10.1016/s0140-6736(74)92085-6. [DOI] [PubMed] [Google Scholar]
  28. Vega G. L., Grundy S. M. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int. 1988 Jun;33(6):1160–1168. doi: 10.1038/ki.1988.125. [DOI] [PubMed] [Google Scholar]
  29. West K. M., Ahuja M. M., Bennett P. H., Czyzyk A., De Acosta O. M., Fuller J. H., Grab B., Grabauskas V., Jarrett R. J., Kosaka K. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983 Jul-Aug;6(4):361–369. doi: 10.2337/diacare.6.4.361. [DOI] [PubMed] [Google Scholar]
  30. Winocour P. H., Durrington P. N., Bhatnagar D., Ishola M., Arrol S., Lalor B. C., Anderson D. C. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus. Diabet Med. 1990 Sep-Oct;7(8):736–743. doi: 10.1111/j.1464-5491.1990.tb01479.x. [DOI] [PubMed] [Google Scholar]
  31. Winocour P. H., Durrington P. N., Ishola M., Anderson D. C., Cohen H. Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987 Jun 27;294(6588):1648–1651. doi: 10.1136/bmj.294.6588.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Winocour P. H., Durrington P. N., Ishola M., Hillier V. F., Anderson D. C. The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med. 1989 Mar;70(263):265–276. [PubMed] [Google Scholar]
  33. Yoshino G., Kazumi T., Iwai M., Matsushita M., Matsuba K., Uenoyama R., Iwatani I., Baba S. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis. 1989 Jan;75(1):67–72. doi: 10.1016/0021-9150(89)90208-6. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES